Alsner Jan, Jensen Vibeke, Kyndi Marianne, Offersen Birgitte Vrou, Vu Phuong, Børresen-Dale Anne-Lise, Overgaard Jens
Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
Acta Oncol. 2008;47(4):600-7. doi: 10.1080/02841860802047411.
p53 accumulation and TP53 mutations are known prognostic markers for breast cancer. To clarify their interrelationship and the importance of different TP53 mutation types, these markers were investigated in tumours from 630 patients with breast cancer.
Tumour sections were stained for p53 and scored based on staining intensity and percentages of invasive tumour cells with nuclear staining. TP53 mutations were identified by sequencing. Patient cohorts were from the DBCG (Danish Breast Cancer Cooperative Group) protocols DBCG82 and DBCG89.
TP53 was mutated in 29% of the patients. The disease-specific survival (DSS) at 15 years of follow-up for patients with missense mutations directly involved in DNA or zinc binding was 21+/-8%. Patients with the remaining missense mutations within the structural/conserved domains and patients with null mutations had a DSS of 36+/-6% and 31+/-17%, respectively. For patients without TP53 mutations and patients with mutations affecting amino acids outside these domains, the 15 year DSS was 51+/-3% and 71+/-10%, respectively. p53 accumulation was successfully scored in 567 patients and categorized into three groups. Tumours with no p53 expression had a high frequency of null mutations (37% compared to 10% in the whole cohort), and tumours with high p53 expression contained 82% of the missense mutations inside structural/conserved domains including those directly involved in DNA or zinc binding.
The clinical outcome for breast cancer patients is significantly different for different TP53 mutation types, but further functional studies are required to clarify the exact role of these mutation types. Most of the mutations that lead to mutant p53 protein accumulation can be detected by immunohistochemistry but the specificity is low. Samples showing lack of detectable p53 protein should be considered as an indication of a possible null mutation.
p53蛋白积累和TP53基因突变是已知的乳腺癌预后标志物。为阐明它们之间的相互关系以及不同TP53基因突变类型的重要性,对630例乳腺癌患者的肿瘤进行了这些标志物的研究。
肿瘤切片进行p53染色,并根据染色强度和侵袭性肿瘤细胞核染色百分比进行评分。通过测序鉴定TP53基因突变。患者队列来自丹麦乳腺癌协作组(DBCG)的DBCG82和DBCG89方案。
29%的患者TP53基因发生突变。随访15年时,直接参与DNA或锌结合的错义突变患者的疾病特异性生存率(DSS)为21±8%。结构/保守结构域内其余错义突变患者和无义突变患者的DSS分别为36±6%和31±17%。对于无TP53基因突变的患者和突变影响这些结构域以外氨基酸的患者,15年DSS分别为51±3%和71±10%。567例患者成功进行了p53蛋白积累评分,并分为三组。无p53蛋白表达的肿瘤无义突变频率较高(37%,而整个队列中为10%),p53蛋白高表达的肿瘤包含82%的结构/保守结构域内的错义突变,包括直接参与DNA或锌结合的错义突变。
不同TP53基因突变类型的乳腺癌患者临床结局有显著差异,但需要进一步的功能研究来阐明这些突变类型的确切作用。大多数导致突变型p53蛋白积累的突变可通过免疫组织化学检测,但特异性较低。显示无法检测到p53蛋白的样本应被视为可能存在无义突变的指征。